Global Drugs & Biologics Update

Europe

Teva withdraws Egranil application

eva Pharma B.V. notified EMA on November 4, 2014 that it was withdrawing its marketing approval application for Egranil for chemo-therapy induced neutropenia. The withdrawal was prompted by corporate marketing strategy and not safety or efficacy concerns.